Table 3.
Examples of the mechanisms of miRNA-mediated resistance in ovarian cancer.
References | miRNA | Expression in resistant cells | Target gene | Suggested mechanism |
---|---|---|---|---|
Xu et al. (148) | miR-497 | Down | mTOR/P70S6K1 | The resultant activation of mTOR/P70S6K1 positively affects several downstream effectors to regulate cell growth, proliferation, and survival (149). |
Chen et al. (150) | miR-133b | Down | GST-π | GSTs have the ability to detoxify cytostatic drugs (151). Therefore, chemotherapy-resistant ovarian cancer cells might develop resistance by upregulating the miR-133b-target gene GST-π. |
van Jaarsveld et al. (152) | miR-634 | Down | CCND1, GRB2, ERK2, and RSK2 | Upregulation and activation of these MAPK pathway components produce undesirable effects on several fundamental cellular processes, including cell cycle progression and inhibition of apoptosis (153). |
Dwivedi et al. (154) | miR-15a miR-16 | Down | BMI1 | Bmi1, a member of the Polycomb Repressor Complex 1, is a crucial regulator of the self-renewal and malignant transformation of many cancers (see Table 2). |
Cui et al. (155) | miR-146a | Down | SOD2 | Resistant cells have shown higher levels of the antioxidant SOD2, which scavenge any reactive species produced by the chemotherapy and thus resist death (156). |
Guo et al. (157) | miR-100 | Down | mTOR and PLK1 | Cells are able to develop resistance by enhancing the functions of the mitotic regulator gene Polo-like kinase 1 (Plk1) (158), in addition to the other oncogenic roles of mTOR (see above). |
Zhu et al. (159) | miR-186 | Down | Twist1 | Twist1 can confer chemoresistance in different cancers by regulating several downstream signaling proteins, including mTOR and Bcl2. In addition, Twist1 binds and activates ABC transporters, mediates EMT-induced resistance, and positively regulates PI3K/AKT pathway (160). |
Han et al. (161) | miR-30a/c-5p | Down | Snail | DNMT1-mediated silencing of miR-30a/c-5p upregulates E-cadherin-transcriptional repressor Snail, thereby promoting EMT-mediated resistance to cisplatin. |
Vera et al. (162) | miR-7 | Down | MAFG | Recent evidence suggests that MAFG confers antioxidant activity against free radicals produced as a result of cisplatin treatment, which might be the mechanism behind MAFG-induced cisplatin resistance (163). |
Jiang et al. (164) | miR-139-5p | Down | C-Jun | The resultant overexpression of the proto-oncogene c-Jun promotes the expression of the anti-apoptotic protein Bcl-XL, thereby suppressing the apoptotic death of these cells. |
Kanlikilicer et al. (165) | miR-1246 | Up | Cav1 | Upregulated miR-1246 potentiates resistance toward paclitaxel through the downregulation of Cav1, a protein that directly binds and inhibits the kinase activity of the platelet-derived growth factor receptor PDGFRβ, which correlates with induction of the p-glycoprotein (MDR1) levels. |
Chen et al. (166) | miR-139-5p | Down | RNF2 | Evidence suggests that ovarian cancer cells can develop resistance by upregulating the ring finger protein 2, RNF2, an E3 ligase that targets the tumor suppressor p53 for degradation, thereby inhibiting cellular apoptosis (167). |
Zhang et al. (168) | miR-1294 | Down | IGF1R | See Table 2 |
Xu et al. (169) | miR-378a-3p | Down | MAPK1/GRB2 | See above |
Jiang et al. (170) | miR-383-5p | Down | TRIM27 | See above |
Sun et al. (171) | miR-137 | Down | EZH2 | EZH2 functions as a transcriptional suppressor or a transcriptional co-activator through epigenetic regulation of histone methylation. Evidence has shown that the upregulation of EZH2 strongly correlates with cisplatin resistance (172, 173). |
Park and Kim (174) | miR-503-5p | Down | CD97 | CD97 is a member of the epidermal growth factor (EGF)-seven transmembrane family that signals through Janus-activated kinase 2(JAK2), a signal transducer and activator of transcription 3 (STAT3), to induce paclitaxel resistance in ovarian carcinoma. |
Nakamura et al. (175) | miR-194-5p | Down | MDM2 | Upregulation of the E3 ubiquitin ligase, MDM2, blocks the transcriptional activity of several tumor suppressor genes, including p53 and p21. |
Li et al. (176) | miR-142-5p | Down | XIAP | See Table 2. |
Zhang et al. (177) | miR-574-3p | Down | EGFR | Cells might confer resistance toward chemotherapies by activating several signaling cascades involved in proliferation and survival that are downstream of the oncogenic EGFR (178). |
Dai et al. (179) | miR-195-5p | Down | PSAT1 | PSAT1-promotes inactivating phosphorylation of GSK3β, allowing the accumulation and nuclear translocation of β-catenin, which might help in conferring resistance by upregulating the stress-related gene, HIF-1α. |